| Literature DB >> 27141339 |
Tong Seng Lim1, Valerie Chew2, Je Lin Sieow3, Siting Goh3, Joe Poh-Sheng Yeong4, Ai Ling Soon3, Paola Ricciardi-Castagnoli5.
Abstract
Programmed death one (PD-1) is a well-established co-inhibitory regulator that suppresses proliferation and cytokine production of T cells. Despite remarkable progress in delineating the functional roles of PD-1 on T lymphocytes, little is known about the regulatory role of PD-1 expressed on myeloid cells such as dendritic cells (DCs). Here, we show that CD8+ T cells can be more potently activated to secrete IL-2 and IFNγ by PD-1-deficient DCs compared to wild-type DCs. Adoptive transfer of PD-1-deficient DCs demonstrated their superior capabilities in inducing antigen-specific CD8+ T cell proliferation in vivo. In addition, we provide first evidence demonstrating the existence of peripheral blood DCs and CD11c+ tumor-infiltrating myeloid cells that co-express PD-1 in patients with hepatocellular carcinoma (HCC). The existence of PD-1-expressing HCC-infiltrating DCs (HIDCs) was further supported in a mouse model of HCC. Intratumoral transfer of PD-1-deficient DCs rendered recipient mice resistant to the growth of HCC by promoting tumor-infiltrating CD8+ effector T cells to secrete perforin and granzyme B. This novel finding provides a deeper understanding of the role of PD-1 in immune regulation and has significant implications for cancer immunotherapies targeting PD-1.Entities:
Keywords: Antitumor immunity; Programmed death one (PD-1); cancer immunotherapy; dendritic cell; hepatocellular carcinoma; liver cancer
Year: 2015 PMID: 27141339 PMCID: PMC4839350 DOI: 10.1080/2162402X.2015.1085146
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110